Lower-Dose Antipsychotics Benefit Patients with Schizophrenia

NEW ORLEANS — Patients with treatment-refractory schizophrenia in a long-term forensic facility showed significant stability following reduced doses of long-acting injectable antipsychotics, a study revealed. Dr Mujeeb Shad “There is an argument by some experts in the field that state hospital populations represent a different set of patients who require higher antipsychotic dosages, with no … Read more

High-Dose Antipsychotics Effective in Refractory Schizophrenia

NEW ORLEANS – Patients with severe schizophrenia who fail to respond to treatment with standard doses of second-generation antipsychotics show significant improvement with – and tolerance of – higher maintenance doses of the drugs, new research shows. Dr Juan Jose Fernandez-Miranda The use of [higher doses of] long-acting injectable second-generation antipsychotics shows improvement not only … Read more

Quick Pivot Upheld Schizophrenia Care During COVID

During the COVID-19 pandemic, mental health clinics in the United States successfully upheld the standard of care for patients with schizophrenia using telepsychiatry and long-acting injectable antipsychotics (LAIs), a new survey data show. “Mental health centers rose to the challenge and did what they needed to do for their patients,” study investigator Dawn Velligan, PhD, … Read more

Novel Long-Acting Injection Cuts Schizophrenia Relapse

A long-acting subcutaneous antipsychotic (LASCA) suspension that combines risperidone with a novel copolymer substantially reduces both risk for relapse and time to impending relapse for patients with schizophrenia, new research suggests. In the phase 3 Risperidone Subcutaneous Extended-release (RISE) trial, which included more than 500 patients with schizophrenia, those who received the novel combination treatment, … Read more